Acorda Therapeutics adds Catherine D. Strader to board
Prior to founding Synergy Partners R&D Solutions, Dr. Strader held executive leadership positions at both Merck, where she was Vice President and Site Head, and Schering-Plough, where she was Executive Vice President of Discovery Research and Chief Scientific Officer.
Dr. Strader has guided more than 50 compounds through drug discovery and development during her career.
At Merck, she led an external research initiative, with responsibility for developing and implementing an integrated strategy for building Merck's early pipeline using external sources of innovation.
At Schering-Plough, Dr. Strader had both strategic and operational responsibility for the company’s global small molecule and biologics discovery research portfolio, when she and her team initiated many of the programs that currently populate the Merck portfolio.
Dr. Strader received her B.S. in Chemistry from the University of Virginia and her Ph.D. in Chemistry from the California Institute of Technology.
Dr. Strader did her postdoctoral training as a Howard Hughes Fellow in Robert Lefkowitz’s laboratory at Duke University and is the author of more than 150 scientific publications. ■
LATEST MOVES FROM New York
- AzurRx BioPharma appoints Vern Lee Schramm to board
- Nature's Bounty appoints Mark Gelbert as CSO
- Global Net Lease appoints Christopher J. Masterson as CFO
- Bristol-Myers Squibb appoints Saurabh Saha as SVP
- GAIN Capital appoints Joseph A. Schenk as chairman
More inside POST